Literature DB >> 29627364

Animal models of cholangiocarcinoma.

Emilien Loeuillard1, Samantha R Fischbach1, Gregory J Gores1, Sumera Rizvi2.   

Abstract

Cholangiocarcinoma (CCA) is an aggressive biliary tract malignancy with a poor overall prognosis. There is a critical need to develop effective targeted therapies for the treatment of this lethal disease. In an effort to address this challenge, preclinical in vivo studies have become paramount in understanding CCA carcinogenesis, progression, and therapy. Various CCA animal models exist including carcinogen-based models in which animals develop CCA after exposure to a carcinogen, genetically engineered mouse models in which genetic changes are induced in mice leading to CCA, murine syngeneic orthotopic models, as well as xenograft tumors derived from xenotransplantation of CCA cells, organoids, and patient-derived tissue. Each type has distinct advantages as well as shortcomings. In the ideal animal model of CCA, the tumor arises from the biliary tract in an immunocompetent host with a species-matched tumor microenvironment. Such a model would also be time-efficient, recapitulate the genetic and histopathological features of human CCA, and predict therapeutic response in humans. Recently developed biliary tract transduction and orthotopic syngeneic transplant mouse models encompass several of these elements. Herein, we review the different animal models of CCA, their advantages and deficiencies, as well as features which mimic human CCA.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Orthotopic; Transduction; Transgenic; Xenotransplantation

Mesh:

Year:  2018        PMID: 29627364      PMCID: PMC6177316          DOI: 10.1016/j.bbadis.2018.03.026

Source DB:  PubMed          Journal:  Biochim Biophys Acta Mol Basis Dis        ISSN: 0925-4439            Impact factor:   5.187


  128 in total

1.  MicroRNA-dependent regulation of DNA methyltransferase-1 and tumor suppressor gene expression by interleukin-6 in human malignant cholangiocytes.

Authors:  Chiara Braconi; Nianyuan Huang; Tushar Patel
Journal:  Hepatology       Date:  2010-03       Impact factor: 17.425

2.  Expression of G1-S modulators (p53, p16, p27, cyclin D1, Rb) and Smad4/Dpc4 in intrahepatic cholangiocarcinoma.

Authors:  Yun Kyung Kang; Woo Ho Kim; Ja June Jang
Journal:  Hum Pathol       Date:  2002-09       Impact factor: 3.466

3.  Thioacetamide-induced intestinal-type cholangiocarcinoma in rat: an animal model recapitulating the multi-stage progression of human cholangiocarcinoma.

Authors:  Chun-Nan Yeh; Anirban Maitra; Kam-Fai Lee; Yi-Yin Jan; Miin-Fu Chen
Journal:  Carcinogenesis       Date:  2003-12-04       Impact factor: 4.944

Review 4.  Biliary proliferation and adaptation in furan-induced rat liver injury and carcinogenesis.

Authors:  A E Sirica
Journal:  Toxicol Pathol       Date:  1996 Jan-Feb       Impact factor: 1.902

Review 5.  Experimental mouse models for hepatocellular carcinoma research.

Authors:  Femke Heindryckx; Isabelle Colle; Hans Van Vlierberghe
Journal:  Int J Exp Pathol       Date:  2009-08       Impact factor: 1.925

6.  A novel "patient-like" model of cholangiocarcinoma progression based on bile duct inoculation of tumorigenic rat cholangiocyte cell lines.

Authors:  Alphonse E Sirica; Zichen Zhang; Guan-Hua Lai; Toru Asano; Xue-Ning Shen; Deanna J Ward; Arvind Mahatme; Jennifer L Dewitt
Journal:  Hepatology       Date:  2008-04       Impact factor: 17.425

7.  Prevention of dual promoting effects of pentachlorophenol, an environmental pollutant, on diethylnitrosamine-induced hepato- and cholangiocarcinogenesis in mice by green tea infusion.

Authors:  Takashi Umemura; Sachie Kai; Ryuichi Hasegawa; Keita Kanki; Yasuki Kitamura; Akiyoshi Nishikawa; Masao Hirose
Journal:  Carcinogenesis       Date:  2003-04-24       Impact factor: 4.944

8.  Autocrine parathyroid hormone-like hormone promotes intrahepatic cholangiocarcinoma cell proliferation via increased ERK/JNK-ATF2-cyclinD1 signaling.

Authors:  Jing Tang; Yan Liao; Shuying He; Jie Shi; Liang Peng; Xiaoping Xu; Fang Xie; Na Diao; Jinlan Huang; Qian Xie; Chuang Lin; Xiaoying Luo; Kaili Liao; Juanjuan Ma; Jingyi Li; Daichao Zhou; Zhijun Li; Jun Xu; Chao Zhong; Guozhen Wang; Lan Bai
Journal:  J Transl Med       Date:  2017-11-25       Impact factor: 5.531

9.  KCa3.1 as an Effective Target for Inhibition of Growth and Progression of Intrahepatic Cholangiocarcinoma.

Authors:  Penghong Song; Yehui Du; Wenfeng Song; Hao Chen; Zefeng Xuan; Long Zhao; Jun Chen; Jian Chen; Danjing Guo; Cheng Jin; Yongchao Zhao; Biguang Tuo; Shusen Zheng
Journal:  J Cancer       Date:  2017-06-03       Impact factor: 4.207

10.  Synergistic antitumor activity of the combination of salubrinal and rapamycin against human cholangiocarcinoma cells.

Authors:  Xiaofang Zhao; Chunyan Zhang; Hong Zhou; Bin Xiao; Ying Cheng; Jinju Wang; Fuli Yao; Chunyan Duan; Run Chen; Youping Liu; Chunhong Feng; Hong Li; Jing Li; Rongyang Dai
Journal:  Oncotarget       Date:  2016-12-20
View more
  17 in total

Review 1.  Cholangiocarcinoma 2020: the next horizon in mechanisms and management.

Authors:  Jesus M Banales; Jose J G Marin; Angela Lamarca; Pedro M Rodrigues; Shahid A Khan; Lewis R Roberts; Vincenzo Cardinale; Guido Carpino; Jesper B Andersen; Chiara Braconi; Diego F Calvisi; Maria J Perugorria; Luca Fabris; Luke Boulter; Rocio I R Macias; Eugenio Gaudio; Domenico Alvaro; Sergio A Gradilone; Mario Strazzabosco; Marco Marzioni; Cédric Coulouarn; Laura Fouassier; Chiara Raggi; Pietro Invernizzi; Joachim C Mertens; Anja Moncsek; Sumera Rizvi; Julie Heimbach; Bas Groot Koerkamp; Jordi Bruix; Alejandro Forner; John Bridgewater; Juan W Valle; Gregory J Gores
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2020-06-30       Impact factor: 46.802

Review 2.  Cholangiocarcinoma: novel therapeutic targets.

Authors:  Keisaku Sato; Shannon Glaser; Domenico Alvaro; Fanyin Meng; Heather Francis; Gianfranco Alpini
Journal:  Expert Opin Ther Targets       Date:  2020-02-26       Impact factor: 6.902

Review 3.  Cholangiocarcinoma.

Authors:  Paul J Brindley; Melinda Bachini; Sumera I Ilyas; Shahid A Khan; Alex Loukas; Alphonse E Sirica; Bin Tean Teh; Sopit Wongkham; Gregory J Gores
Journal:  Nat Rev Dis Primers       Date:  2021-09-09       Impact factor: 65.038

4.  New molecular mechanisms in cholangiocarcinoma: signals triggering interleukin-6 production in tumor cells and KRAS co-opted epigenetic mediators driving metabolic reprogramming.

Authors:  Leticia Colyn; Gloria Alvarez-Sola; M Ujue Latasa; Carmen Berasain; Maite G Fernandez-Barrena; Matias A Avila; Iker Uriarte; Jose M Herranz; Maria Arechederra; George Vlachogiannis; Colin Rae; Antonio Pineda-Lucena; Andrea Casadei-Gardini; Federica Pedica; Luca Aldrighetti; Angeles López-López; Angeles López-Gonzálvez; Coral Barbas; Sergio Ciordia; Sebastiaan M Van Liempd; Juan M Falcón-Pérez; Jesus Urman; Bruno Sangro; Silve Vicent; Maria J Iraburu; Felipe Prosper; Leonard J Nelson; Jesus M Banales; Maria Luz Martinez-Chantar; Jose J G Marin; Chiara Braconi; Christian Trautwein; Fernando J Corrales; F Javier Cubero
Journal:  J Exp Clin Cancer Res       Date:  2022-05-26

5.  Gut Microbiome Directs Hepatocytes to Recruit MDSCs and Promote Cholangiocarcinoma.

Authors:  Qianfei Zhang; Chi Ma; Yi Duan; Bernd Heinrich; Umberto Rosato; Laurence P Diggs; Lichun Ma; Soumen Roy; Qiong Fu; Zachary J Brown; Simon Wabitsch; Vishal Thovarai; Jianyang Fu; Dechun Feng; Benjamin Ruf; Linda L Cui; Varun Subramanyam; Karen M Frank; Sophie Wang; David E Kleiner; Thomas Ritz; Christian Rupp; Bin Gao; Thomas Longerich; Alexander Kroemer; Xin Wei Wang; Mathuros Ruchirawat; Firouzeh Korangy; Bernd Schnabl; Giorgio Trinchieri; Tim F Greten
Journal:  Cancer Discov       Date:  2020-12-15       Impact factor: 38.272

6.  Matrisome analysis of intrahepatic cholangiocarcinoma unveils a peculiar cancer-associated extracellular matrix structure.

Authors:  Guido Carpino; Diletta Overi; Fabio Melandro; Alessio Grimaldi; Vincenzo Cardinale; Sabina Di Matteo; Gianluca Mennini; Massimo Rossi; Domenico Alvaro; Vincenzo Barnaba; Eugenio Gaudio; Carmine Mancone
Journal:  Clin Proteomics       Date:  2019-10-30       Impact factor: 3.988

Review 7.  Cholangiocarcinoma: bridging the translational gap from preclinical to clinical development and implications for future therapy.

Authors:  Leonardo Baiocchi; Keisaku Sato; Burcin Ekser; Lindsey Kennedy; Heather Francis; Ludovica Ceci; Ilaria Lenci; Domenico Alvaro; Antonio Franchitto; Paolo Onori; Eugenio Gaudio; Chaodong Wu; Sanjukta Chakraborty; Shannon Glaser; Gianfranco Alpini
Journal:  Expert Opin Investig Drugs       Date:  2020-12-08       Impact factor: 6.206

Review 8.  Organoids and Spheroids as Models for Studying Cholestatic Liver Injury and Cholangiocarcinoma.

Authors:  Burcin Ekser; Gianfranco Alpini; Keisaku Sato; Wenjun Zhang; Samira Safarikia; Abdulkadir Isidan; Angela M Chen; Ping Li; Heather Francis; Lindsey Kennedy; Leonardo Baiocchi; Domenico Alvaro; Shannon Glaser
Journal:  Hepatology       Date:  2021-06-04       Impact factor: 17.298

Review 9.  In Vivo Models for Cholangiocarcinoma-What Can We Learn for Human Disease?

Authors:  Raphael Mohr; Burcin Özdirik; Jana Knorr; Alexander Wree; Münevver Demir; Frank Tacke; Christoph Roderburg
Journal:  Int J Mol Sci       Date:  2020-07-15       Impact factor: 5.923

10.  Liver fluke granulin promotes extracellular vesicle-mediated crosstalk and cellular microenvironment conducive to cholangiocarcinoma.

Authors:  Patpicha Arunsan; Apisit Chaidee; Christina J Cochran; Victoria H Mann; Toshihiko Tanno; Chutima Kumkhaek; Michael J Smout; Shannon E Karinshak; Rutchanee Rodpai; Javier Sotillo; Alex Loukas; Thewarach Laha; Paul J Brindley; Wannaporn Ittiprasert
Journal:  Neoplasia       Date:  2020-03-31       Impact factor: 5.715

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.